Rolf‐Peter Müller

Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma

Andreas Engert, Annette Plütschow, Hans Theodor Eich et al. · New England Journal of Medicine · 2010 · 921 citations · Full text

Medicine, Oncology, Chemotherapy +8

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

Andreas Engert, Heinz Haverkamp, Carsten Kobe et al. · The Lancet · 2012 · 632 citations

Medicine, Oncology, Radiation Oncology +15

Involved-Field Radiotherapy Is Equally Effective and Less Toxic Compared With Extended-Field Radiotherapy After Four Cycles of Chemotherapy in Patients With Early-Stage Unfavorable Hodgkin’s Lymphoma: Results of the HD8 Trial of the German Hodgkin’s Lymphoma Study Group

Andreas Engert, Petra Schiller, Andreas Josting et al. · Journal of Clinical Oncology · 2003 · 461 citations

Medicine, Oncology, Radiation Oncology +14

Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial

Hans Theodor Eich, Volker Diehl, Helen Görgen et al. · Journal of Clinical Oncology · 2010 · 436 citations · Full text

Medicine, Oncology, Radiation Oncology +16

Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial

Andreas Engert, Jeremy Franklin, Hans Theodor Eich et al. · Journal of Clinical Oncology · 2007 · 261 citations · Full text

Medicine, Oncology, Radiation Oncology +16